| DuoNeb Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| DuoNeb 2.5 mg-0.5 mg/3 mL | solution | inhalation | 3.0 milliliter(s) | OTC |
| DuoNeb 2.5 mg-0.5 mg/3 mL | solution | inhalation | 3.0 milliliter(s) | OTC |
Posted by pbanet over 3 years ago
Enlarged prostate
Posted by xpapermaker over 5 years ago
hoarness in the throat, dry throat
FDA approves Watson respiratory drug - CNBC
... Pharmaceuticals Inc. said Wednesday the Food and Drug Administration approved its generic version of Dey LP's respiratory condition treatment DuoNeb. ...
Wed Jan 02 15:53:37 -0500 2008
Teva Gets FDA Approval To Sell Generic Version Of Dey LP's ... - Trading Markets (press release)
DuoNeb had annual sales of about $265 million in the United States for the 12 months ended September 30. FinancialWire is an independent, proprietary news ...
Thu Jan 03 08:16:01 -0500 2008
Teva gets FDA OK for generic of Dey's DuoNeb - Reuters
TA said the US Food and Drug Administration gave final approval for a generic version of Dey LP's bronchodilator, DuoNeb. Shipment of the inhalation ...
Thu Jan 03 01:03:18 -0500 2008
albuterol - A racemic mixture of the r-isomer levalbuterol and s-albuterol, a short-acting sympathomimetic agent with bronchodilator activity. Albuterol stimulates beta2-adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells. Albuterol although to a lesser extent, also stimulates beta1-adrenergic receptors, thereby increasing the force and rate of myocardial contraction.
ipratropium bromide - The bromide salt form of ipratropium, a synthetic derivative of the alkaloid atropine with anticholinergic properties. Ipratropium antagonizes the actions of acetylcholine at parasympathetic, postganglionic, effector-cell junctions. When inhaled, ipratropium binds competitively to cholinergic receptors in the bronchial smooth muscle thereby blocking the bronchoconstrictor actions of the acetylcholine (Ach) mediated vagal impulses. Inhibition of the vagal tone leads to dilation of the large central airways resulting in bronchodilation.